Crescent Biopharma Inc. (CBIO) Financial Ratios & Valuation Metrics Analysis - P/E, ROE, Debt Ratios & Profitability - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Crescent Biopharma Inc.

    NASDAQ: CBIO · Real-Time Price · USD
    11.72
    -0.31 (-2.58%)
    At close: Oct 03, 2025, 3:59 PM
    11.72
    0.00%
    After-hours: Oct 03, 2025, 05:45 PM EDT

    Crescent Biopharma Ratios and Metrics

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    PE Ratio
    		 -42.38 -405.12 -340.92 -116.81
    PEG Ratio
    		 -24.58 11.63 12.33 -11.89
    PS Ratio
    		 n/a 1.49M 212.23K 6.39K
    PB Ratio
    		 -139.86 389.15 370.77 90.80
    P/FCF Ratio
    		 -51.61 -428.32 -341.99 -128.85
    P/OCF Ratio
    		 -51.63 -428.58 -342.61 -128.88
    OCF/S Ratio
    		 n/a -3.49K -619.43 -49.57
    Debt / Equity Ratio
    		 -3.27 0.02 0.02 0.02
    Quick Ratio
    		 3.62 6.41 5.73 7.72
    Current Ratio
    		 3.62 6.41 5.71 7.68
    Asset Turnover
    		 n/a 0.00 0.00 0.01
    Interest Coverage
    		 n/a n/a n/a n/a
    Return on Equity
    		 3.30 -0.96 -1.09 -0.78
    Return on Assets
    		 -1.06 -0.81 -0.9 -0.67
    Return on Invested Capital
    		 -1.25 -0.98 -1.06 -0.75
    Dividend Yield
    		 n/a n/a n/a n/a
    Payout Ratio
    		 n/a n/a n/a n/a
    Gross Profit Margin
    		 n/a 1.00 1.00 1.00
    Net Profit Margin
    		 n/a -3.69K -622.52 -54.69
    Pretax Profit Margin
    		 n/a -3.69K -622.51 -54.69
    Operating Profit Margin
    		 n/a -3.93K -632.04 -54.71
    FCF Margin
    		 n/a -3.49K -620.56 -49.58
    EBITDA Margin
    		 n/a -3.91K -629.28 -54.48

    Add to Watchlist